TO THE EDITOR Transgenic mouse models of melanoma driven by melanocyte-specific expression of oncogenes have been developed to study gene-gene and gene-environment interactions (Damsky and Bosenberg, 2010) . Oncogene expression can be constitutive or inducible, but is generally insufficient for melanomagenesis unless tumor-suppressor genes are deleted (Pten, Tp53, Cdkn2a), or the mice are exposed to mutagens such as UV light. Critically, in mice melanoma is largely restricted to the dermal layers of the skin and the epidermis is rarely involved, whereas human cutaneous malignant melanoma generally develops in the epidermis and then invades the deeper layers of skin. This difference presumably occurs because mouse melanocytes are predominantly located in the follicles and dermis and provide pelt pigmentation, whereas human melanocytes are predominantly epidermal and provide protection from UV light.
Melanocyte location in the skin is controlled by the KIT ligand (KITL). Human keratinocytes express KITL throughout life and melanocytes persist in the epidermis. In postnatal mouse skin, KITL expression is restricted to the hair matrix (Yoshida et al., 2001) and the melanocytes are largely located in the follicles. However, if mouse keratinocytes are engineered to express KITL using the keratin-14 gene promoter (K14-Kitl), a proportion of the melanocytes remain in the epidermis throughout life (Kunisada et al., 1998) . Using this approach, melanoma driven by tyrosinase-expressed Q61K Nras (Tyr-Q61K Nras), p19 Arf deletion, and neonatal UV light exposure can be translocated to the mouse epidermis (Walker et al., 2011) .
The protein kinase BRAF is mutated in about half of human melanomas and we developed a V600E Braf-driven mouse melanoma model using the tamoxifen-activated Cre-recombinase/ loxP technology (Dhomen et al., 2009) . V600E Braf-driven melanomas are exclusively dermal (Dhomen et al., 2009 ); therefore we tested whether a membrane-bound version of KITL under the control of the K14 promoter could translocate these tumors to the epidermis. All animal procedures were approved by the local animal ethics committee (ICR) in accordance with the Home Office regulations under the Animals (Scientific Procedures) Act of 1986 (Workman et al., 2010) . When LSL-V600E Braf::Tyr-CreERT2 (henceforth V600E Braf) mice were crossed with K14-Kitl mice, we observed S100-positive melanocytes in the basal layers of the interfollicular epidermis ( Figure 1a ) and melanin capping of the nuclei in the keratinocytes (Figure 1b ). These features were absent in V600E Braf mice (Figures 1a and b ). As previously described (Dhomen et al., 2009) , V600E Braf induced mild hyperpigmentation of the ears and feet (Figure 1c ). Notably, KITL also induced increased pigmentation of the feet and ears and V600E Braf further enhanced this effect ( Figure 1c ).
V600E
Braf also induced nevi comprising pigmented epithelioid and dendritic melanocytes in the deep reticular dermis and hypodermis of the skin ( Figure  1d ; see Dhomen et al., 2009) . However, in V600E Braf::K14-Kitl mice, V600E Braf induced highly cellular nevi presenting large populations of pig-ment-laden epithelioid and dendritic melanocytes that occasionally formed ill-defined nests (Figure 1d ; Supplementary Figure S1 online). Nevi in V600E Braf::K14-Kitl mice were located in the papillary and reticular dermis and were separated from the epidermis by a narrow Grenz zone. They occasionally reached the hypodermis surrounding the adnexae, but did not present an epidermal component (Figure 1d ; Supplementary Figure S1 online).
Braf also induced rapidly growing skin tumors in V600E Braf and V600E Braf::K14-Kitl mice (Figure 2a ). The tumors from the two strains of mice were macroscopically similar, but developed with a significantly lower latency in the V600E Braf::K14-Kitl mice (4.8 compared with 12.5 months; logrank test Po0.0001; Figure 2b ). V600E Braf::K14-Kitl mice also showed greater tumor penetrance (100% in 7 months compared with 70% in 24 months; Figure 2b ) and developed a greater number of tumors (average 3 compared with 0.78; Figure 2c ).
Using PCR, we showed that LSL-V600E Braf was recombined in tumors from V600E Braf::K14-Kitl mice (Figure 2d ), and using RT-PCR we confirmed the expression of the melanocytic markers tyrosinase, silver (gp100), Mitf-M, Dct (Trp2), Sox10, Pax3, and Pou3f2 (Brn2; Figure 2e ). S100 expression was confirmed by immunostaining ( Figure 2f ). These data are consistent with a diagnosis of malignant melanoma. The smaller, less advanced tumors presented an intact epidermis and pigmented melanocytes in the reticular dermis, suggestive of residual intradermal nevi (Figure 2g ). These lesions were generally amelanotic, paucicellular, and composed of spindle/dendritic melanocytes occupying the deeper layers of skin ( Figure 2h ). The larger lesions were generally asymmetric, poorly circumscribed, and within the superficial dermis (Figure 2i ). Prominent ulceration and effacement of the epidermis were common (Figure 2j ), as was locally destructive invasion into the subcutaneous layers (Figure 2i and k). These tumors were also generally amelanotic, with rare pigmented melanocytes occupying the superficial aspects. The deeper aspects were composed of atypical spindle melanocytes occasionally arranged in storiform patterns (Figure 2l ). Mitotic figures were abundant (Figure 2m ). Crucially, as in V600E Braf mice (Dhomen et al., 2009) , the tumors in V600E Braf::K14-Kitl mice were exclusively dermal; neither epidermal invasion nor a junctional component was observed (Figures 2g, i , j, and l), and we note that K14-Kitl also failed to translocate melanoma driven by the metabotropic glutamate receptor-1 (mGluR1) to the epidermis (Abdel-Daim et al., 2010) .
We set out to translocate V600E Braf tumors to the epidermis using K14-Kitl. We cannot discount the possibility that rare melanoma cells did colonize the epidermis, but overall the V600E Braf:: K14-Kitl melanomas appeared to be exclusively dermal. This may be because, although melanocytes do occupy the epidermis of V600E Braf::K14-Kitl
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V600E Braf S100 S100 Figure  S2 online) ; therefore, the probability of developing dermal melanoma may simply be higher. However, we examined 30 tumors and B50 nevi and found no evidence of epidermal lesions, suggesting that these are not chance events and that even when expressing KITL, the (no. 453, no. 804, and no. 806 ). mouse epidermis does not provide the microenvironment necessary for V600E Braf-driven melanomagenesis.
There are several plausible explanations as to why epidermal melanoma developed in the Tyr-Q61K Nras:: p19 ArfÀ/À ::K14-Kitl, but not in the V600E Braf::K14-Kitl or mGluR1::K14-Kitl mice. UV light is critical for efficient melanomagenesis in Tyr-Q61K Nras:: p19 ArfÀ/À mice (Ferguson et al., 2010) and has been shown to recruit melanocytes to the epidermis of neonatal mice (Walker et al., 2009) . Perhaps the exogenous KITL traps these newly recruited melanocytes and simply increases the chance that epidermal melanoma will develop, or perhaps it provides a microenvironment that supports melanomagenesis in this population in this location. Alternatively, differences in the timing of oncogene expression (prenatal in Tyr-Q61K Nras:: p19 ArfÀ/À mice, induced in juveniles in V600E Braf::K14-Kitl and mGluR1:: K14-Kitl mice), whether p19 Arf is deleted or not, or the genetic background of the mice (pure C57BL6 compared with mixed FVB/C57BL6) could account for the differences. Clearly, these are testable hypotheses and, although the KITL did not translocate V600E Braf melanoma to the epidermis, it increased tumor penetrance and reduced tumor latency and does therefore provide a considerably more robust and versatile mouse model of melanoma.
